Ruoxiang Wang
Overview
Explore the profile of Ruoxiang Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1624
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Waldron R, Wang R, Shishido S, Lugea A, Ibrahim A, Mason J, et al.
Cancer Lett
. 2025 Feb;
614:217546.
PMID: 39952600
Metastatic pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with limited efficacious therapeutic options. Recent investigations have provided proof of concept that circulating tumor cells (CTCs) are reduced by purification...
2.
Huang M, Wang W, Wang Y, Wang R, Pan L, Li X, et al.
J Mater Chem B
. 2024 Nov;
13(1):256-263.
PMID: 39530533
Malignant tumors pose substantial treatment challenges due to their heterogeneity, metastatic potential, and therapeutic resistance, underscoring the urgent need for more effective treatment options. In this study, a novel radionuclide...
3.
Shishido S, Suresh D, Courcoubetis G, Ye B, Lin E, Mason J, et al.
BJC Rep
. 2024 Nov;
2(1):47.
PMID: 39516545
Background: Cancer becomes lethal as it spreads from the primary site to the rest of the body. Circulating tumor cells (CTCs) are biomarkers of disease progression and have been associated...
4.
Lim A, Edderkaoui M, Zhang Y, Wang Q, Wang R, Pandol S, et al.
Int Immunopharmacol
. 2024 Mar;
131:111878.
PMID: 38493693
Background: Kidney renal papillary cell carcinoma (KIRP) is frequently associated with an unfavorable prognosis for affected individuals. Unfortunately, there has been insufficient exploration in search for a reliable prognosis signature...
5.
Wang R, Hu P, Wang F, Lyu J, Ou Y, Edderkaoui M, et al.
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473313
Tumor cells gain advantages in growth and survival by acquiring genotypic and phenotypic heterogeneity. Interactions with bystander cells in the tumor microenvironment contribute to the progression of heterogeneity. We have...
6.
Ou Y, Chu G, Lyu J, Yin L, Lim A, Zhai N, et al.
Mol Pharm
. 2024 Jan;
21(2):873-882.
PMID: 38229228
Prostate cancer (PC), particularly its metastatic castration-resistant form (mCRPC), is a leading cause of cancer-related deaths among men in the Western world. Traditional systemic treatments, including hormonal therapy and chemotherapy,...
7.
Shen Q, Peng L, Zhang Y, Wang R
Front Oncol
. 2023 Jul;
13:1234727.
PMID: 37397385
No abstract available.
8.
Mrdenovic S, Wang Y, Yin L, Chu G, Ou Y, Lewis M, et al.
BMC Cancer
. 2023 Jun;
23(1):499.
PMID: 37268911
Background: Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer and is notorious for its resistance to both chemotherapy and small-molecule inhibitor targeted therapies. Subcellular...
9.
Ou Y, Wang R, Chu G, Elmadbouh O, Lim A, Chung L, et al.
Adv Ther (Weinh)
. 2023 Jan;
5(10).
PMID: 36590644
Pancreatic ductal adenocarcinoma (PDAC) is a disease with no effective therapeutics. We have developed a novel targeted therapy drug consisting of a tumor-targeting ligand, near-infrared (NIR) organic heptamethine carbocyanine dye...
10.
Pu D, Yin L, Zhai X, Wang R, Huang L, Wu Q, et al.
Sci China Life Sci
. 2022 Dec;
66(5):1196-1199.
PMID: 36580164
No abstract available.